Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Unknown 1Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Multiple Myeloma 202Recurrence 53Neoplasms, Plasma Cell 19Neoplasms 12Immunoglobulin Light-chain Amyloidosis 10Hematologic Diseases 4Amyloidosis 4Renal Insufficiency 3Lymphoma, Non-Hodgkin 3Blood Protein Disorders 3Plasmacytoma 2Paraproteinemias 2Neoplasms by Histologic Type 2Disease Progression 2Chromosome 17 deletion 2Waldenstrom Macroglobulinemia 1Smoldering Multiple Myeloma 1Proteostasis Deficiencies 1Malignant Plasma Cell Neoplasms 1Lymphoma, T-Cell, Peripheral 1Leukemia, Plasma Cell 1Leukemia, Myeloid, Acute 1Hypoxia 1Hodgkin Disease 1Hematologic Neoplasms 1Disease 1Corneal Diseases 1Alzheimer Disease 1

Interventions

Dexamethasone 6Lenalidomide 4Bortezomib 4pomalidomide 3isatuximab 2daratumumab 2ricolinostat 1nirogacestat 1ficlatuzumab 1Zoledronic Acid 1Vorinostat 1Ranitidine 1KW-2478 1Hsp90 inhibitor KU757 1Erlotinib Hydrochloride 1Diphenhydramine 1Denosumab 1Cyclophosphamide 1CLR1404 1Acetaminophen 1ARQ531 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Blood Protein Disorders × pomalidomide × Plasma cell × Clear all
NCT01997840 2025-03-04

ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma

Celgene

Phase 1/2 Terminated
103 enrolled 21 charts
Plasma cell

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Plasma Cell

NCT05581875 2022-10-17

A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory

Hellenic Society of Hematology

Phase 1/2 Not yet recruiting
48 enrolled
Plasma cell

Blood Protein Disorders, Corneal Diseases, Hematologic Diseases, Multiple Myeloma, Neoplasms, Paraproteinemias, Neoplasms, Plasma Cell

NCT05298683 2022-03-28

A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor

Hellenic Society of Hematology

Phase 2 Unknown
108 enrolled
Plasma cell

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Renal Insufficiency, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡